Granules India Ltd receives Form 483 with 1 observation from USFDA for Bonthapally API unit 1

Granules India Ltd's API Unit-I facility located at Bonthapally Village, Sangareddy District, Hyderabad, Telangana, India has completed a US FDA inspection from June 16, 2025 to June 20, 2025 with 1 (one) 483 observation. The Company will respond to this observation within the stipulated time.

Bonthapally facility is one of the world's largest single-site Paracetamol API manufacturing plants by volume. Along with Paracetamol APIs, the Company has established Metformin and Guaifenesin API manufacturing plants in the same facility.

Shares of Granules India Limited was last trading in BSE at Rs. 486.85 as compared to the previous close of Rs. 480.40. The total number of shares traded during the day was 29307 in over 1469 trades.

The stock hit an intraday high of Rs. 490.50 and intraday low of 478.80. The net turnover during the day was Rs. 14183300.00.

Source : Equity Bulls

Keywords

GranulesIndia INE101D01020 Pharmaceuticals Form483 1Observation USFDA Bonthapally APIUnit1